<DOC>
	<DOCNO>NCT00077844</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety intravenous enoxaparin versus intravenous unfractionated heparin ( UFH ) patient undergo non-emergent PCI , assess measure incidence non-coronary artery bypass graft ( CABG ) major minor bleeding .</brief_summary>
	<brief_title>Safety Efficacy Enoxaparin Percutaneous Coronary Intervention ( PCI ) Patients , International Randomized Evaluation ( STEEPLE )</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA Male nonpregnant female great equal 18 year age Undergoing nonemergent single multiple sites/vessels PCI procedure PCI perform femoral approach EXCLUSION CRITERIA Known suspect pregnancy woman childbearing potential Thrombolytic therapy within previous 24 hour Undergoing primary PCI ongoing STsegment elevation myocardial infarction ( STEMI ) Undergoing rescue PCI fail thrombolysis Any elective PCI schedule within follow 30 day index PCI Increased bleed risk : ischemic stroke within last year previous hemorrhagic stroke , intracranial tumor aneurysm ; recent ( &lt; 1 month ) trauma major surgery ( include bypass surgery ) ; active bleeding Uncontrolled arterial hypertension Recent ( &lt; 48 hour ) plan spinal/epidural anesthesia puncture Impaired haemostasis : know International Normalized Ratio ( INR ) &gt; 1.5 ; past present bleed disorder ( include congenital bleeding disorder von Willebrand 's disease hemophilia , acquire bleeding disorder , unexplained clinically significant bleed disorder ) , thrombocytopenia ( platelet count &lt; 100,000/ÂµL ) History hypersensitivity contraindication heparin LMWH Treatment oral anticoagulant therapy within 72 hour prior inclusion current need vitaminK antagonist therapy Treatment direct thrombin inhibitor , low molecular weight heparin , unfractionated heparin within 24 hour precede enrolment Use abciximab within previous 7 day , tirofiban , eptifibatide within past 12 hour index PCI Inability give inform consent high likelihood unavailable followup Treatment investigational agent device within previous 30 day , plan use investigational drug device , previous enrollment trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>